April 12, 2019 10:58 AM EDT

Merck's Keytruda wins US approval for wider lung cancer population; CymaBay breaks out positive data from ongoing PBC study

Natalie Grover

Reporter

→ Days after Merck’s entrenched flagship Keytruda immunotherapy scored a key lung cancer approval in China, the drugmaker has expanded its lung cancer market …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Keytruda wins US approval for wider lung cancer population; CymaBay breaks out positive data from ongoing PBC study

Natalie Grover

Reporter

Sign up to read this article for free.

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Merck’s long-awaited obesity move is an oral GLP-1 from China

Post-Hoc: Biosecure is dead. Long live Biosecure?

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

Mer­ck­'s Keytru­da wins US ap­proval for wider lung can­cer pop­u­la­tion; CymaBay breaks out pos­i­tive da­ta from on­go­ing PBC study

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure?

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Merck's Keytruda wins US approval for wider lung cancer population; CymaBay breaks out positive data from ongoing PBC study

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Merck’s long-awaited obesity move is an oral GLP-1 from China

Post-Hoc: Biosecure is dead. Long live Biosecure?

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target